CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 274 enrolled
Drug / intervention
BMS-986213 +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03662659
NCT03662659Phase 2Completed
CompareCT.gov

A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Bristol-Myers Squibb·interventional·Posted Sep 7, 2018·Updated Feb 5, 2025

In Brief

A Phase 2 clinical trial evaluating BMS-986213, Nivolumab, and 3 other interventions for Gastric Cancer and 2 related conditions. Completed, enrolled 274 participants across 79 sites in 17 countries.

Detailed Summary

The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Cancer of the Stomach, Esophagogastric Junction
CountriesArgentina, Australia, Austria, Belgium, Canada, Chile, Czechia, France, Germany, Italy, Norway, Poland, Puerto Rico, Singapore, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 7, 2018
Enrollment StartOct 16, 2018
Primary CompletionAug 27, 2020
Study CompletionJan 18, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.8 years ago

Interventions

BMS-986213biological

Relatlimab + Nivolumab specified dose on specified days

Nivolumabbiological

Specified dose on specified days

XELOXdrug

Oxaliplatin + capecitabine

FOLFOXdrug

Oxaliplatin + leucovorin + fluorouracil

SOXdrug

Oxaliplatin + tegafur/gimeracil/oteracil potassium